Kinase inhibitors

Patent metadata

Field	Value
Publication number	US-9315503-B2
Application number	US-201514819722-A
Country	US
Kind code	B2
Filing date	Aug 6, 2015
Priority date	Dec 9, 2011
Publication date	Apr 19, 2016
Grant date	Apr 19, 2016

Abstract

Compounds of formula (I) and pharmaceutically acceptable salts thereof:

wherein R 2 , W, A, Y and R 1 are as defined in the specification, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.

First claim

The invention claimed is:

1. A method of treating a disease or condition in a human subject which benefits from inhibition of p38 MAP kinase activity, comprising administering, to a subject in need thereof, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof:

wherein;
W is N substituted with hydrogen;
Y is O;
R 1 is a group represented by formula (IIc):

X 2 is a —CH— group, X 3 is a nitrogen atom, X 4 is a carbon atom, and X 5 is a nitrogen atom;
R 11 is linked to X 4 and is C 1 -C 6 alkyl which is substituted by —OR C or —SR C ; —NR A R B ; —(C 1 -C6)alkylene-NR A R B ; or —(C 3 -C 7 )heterocycloalkyl, wherein any of said NR A R B , —(C 1 -C 6 )alkylene-NR A R B , or —(C 3 -C 7 )heterocycloalkyl may be optionally substituted by one or two C 1 -C 6 alkyl;
R A and R B form, together with the nitrogen atom to which they are attached, a 5-11-membered saturated heterocyclic monocyclic ring system which is optionally substituted by one or more C 1 -C 6 alkyl and which 5-11-membered saturated heterocyclic monocyclic ring optionally contains a further heteroatom which is oxygen or nitrogen;
R C is at each occurrence independently hydrogen or C 1 -C 6 alkyl, said C 1 -C 6 alkyl being optionally substituted —OR D ;
R D is at each occurrence independently hydrogen, —CH 3 , or —C 2 H 5 ;
R 13 is independently hydrogen, C 1 -C 6 alkyl, or halogen;
A is a group represented by one of the following formulae:

and
R 2 is a group of formula (IIIa):

wherein
R 14 , R 15 , and R 16 are —CH 3 ,
wherein said disease or condition is chronic obstructive pulmonary disease, chronic bronchitis, lung fibrosis, pneumonia, acute respiratory distress syndrome, adult respiratory distress syndrome, emphysema, asthma, cystic fibrosis, pulmonary fibrosis, bronchiectasis, exacerbation of airways hyper-reactivity consequent to other drug therapy, or airways disease that is associated with pulmonary hypertension.

2. A method according to claim 1 , wherein said compound or pharmaceutically acceptable salt thereof is a compound of formula (Ia) or pharmaceutically acceptable salt thereof wherein the carbon stereogenic center on the cycloalkylene portion of ring A which is linked to group W and identified with number (1) herebelow, possess the absolute configuration herebelow represented:

3. A method according to claim 1 , wherein said compound or pharmaceutically acceptable salt thereof is a compound of formula (Ib) or pharmaceutically acceptable salt thereof wherein the carbon stereogenic centers on the cycloalkylene portion of ring A which are linked to group W and Y and identified, respectively, with numbers (1) and (2) herebelow, possess the absolute configuration herebelow represented:

4. A method according to claim 1 , wherein R 11 is a group:

wherein R 25 is optionally present and represents one, two, or three substituents independently selected from the group consisting of C 1 -C 6 alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 4 )hydroxyalkyl, C 3 -C 7 cycloalkyl, hydroxyl, and halo; and wherein the asterisk represents the point of attachment for group R 11 to the rest of the molecule via X 4 .

5. method according to claim 1 , wherein R 11 is a group:

wherein R 25 is optionally present and represents one, two, or three substituents independently selected from the group consisting of C 1 -C 6 alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 4 )hydroxyalkyl, C 3 -C 7 cycloalkyl, hydroxyl, and halo; and wherein the asterisk represents the point of attachment for group R 11 to the rest of the molecule via X 4 .

6. A method according to claim 1 , wherein A is a group represented by the following formula:

7. A method according to claim 1 , wherein R 11 is linked to X 4 and is NR A R B and R A and R B form, together with the nitrogen atom to which they are attached, a 5-11-membered saturated heterocyclic monocyclic ring system which is optionally substituted by one or more C 1 -C 6 alkyl and which 5-11-membered saturated heterocyclic monocyclic ring optionally contains a further heteroatom which is oxygen or nitrogen.

8. A method according to claim 1 , wherein said disease or condition is chronic eosinophilic pneumonia, asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, exacerbation of airways hyper-reactivity consequent to other drug therapy or airways disease that is associated with pulmonary hypertension.

9. A method according to claim 8 , wherein said compound or pharmaceutically acceptable salt thereof is a compound of formula (Ia) or pharmaceutically acceptable salt thereof wherein the carbon stereogenic center on the cycloalkylene portion of ring A which is linked to group W and identified with number (1) herebelow, possess the absolute configuration herebelow represented:

10. A method according to claim 8 , wherein said compound or pharmaceutically acceptable salt thereof is a compound of formula (Ib) or pharmaceutically acceptable salt thereof wherein the carbon stereogenic centers on the cycloalkylene portion of ring A which are linked to group W and Y and identified, respectively, with numbers (1) and (2) herebelow, possess the absolute configuration herebelow represented:

11. A method according to claim 8 , wherein R 11 is a group:

wherein R 25 is optionally present and represents one, two, or three substituents independently selected from the group consisting of C 1 -C 6 alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 4 )hydroxyalkyl, C 3 -C 7 cycloalkyl, hydroxyl, and halo; and wherein the asterisk represents the point of attachment for group R 11 to the rest of the molecule via X 4 .

12. A method according to claim 8 , wherein R 11 is a group:

wherein R 25 is optionally present and represents one, two, or three substituents independently selected from the group consisting of C 1 -C 6 alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 4 )hydroxyalkyl, C 3 -C 7 cycloalkyl, hydroxyl, and halo; and wherein the asterisk represents the point of attachment for group R 11 to the rest of the molecule via X 4 .

13. A method according to claim 8 , wherein A is a group represented by the following formu

Assignees

• Chiesi Farma Spa

Inventors

• Van Niel Monique Bodil
• Ray Nicholas Charles
• Alcaraz Lilian
• Panchal Terry Aaron
• Jennings Andrew Stephen Robert
• Armani Elisabetta
• Cridland Andrew Peter
• Hurley Christopher

Classifications

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• A61P11/06

  Antiasthmatics · CPC title